TORONTO — A team of Canadian and U.S. researchers has developed a new “sharp-shooter” drug they hope may be a breakthrough in treating several types of aggressive cancer.
The drug, known for now as CFI-400945, is a new class of cancer agent that targets an enzyme involved in some malignancies, among them certain types of breast cancer, and ovarian, colorectal, pancreatic and prostate cancers.
In tests on specially bred lab mice with human breast and ovarian cancers, CFI-400945 “responded spectacularly,” significantly shrinking the tumours, said co-principal investigator Dr. Tak Mak of Princess Margaret Cancer Centre.
‘To find a cure is our shared dream; our nightmare is that it is not yet within our reach’
But the world-renowned researcher cautioned these results occurred in mice — and human cancers can be far more complex.
“To find a cure is our shared dream; our nightmare is that it is not yet within…
View original post 909 more words